OncRef

Clinical Trial: NCT06498479

ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Hansoh BioMedical R&D Company
Information Provided By:Hansoh BioMedical R&D Company
Last Update Posted:2026-10-16

Study Overview

Brief Summary

The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).

Official Title

ARTEMIS-008:A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Conditions

Small Cell Lung Cancer

Intervention / Treatment

  • Drug: HS-20093
  • Drug: Topotecan

Other Study ID Numbers

  • HS-20093-301

Start Date (Actual)

2024-07-04

Primary Completion Date (Actual)

2026-08-20

Study Completion Date (Actual)

2026-08-20

Enrollment (Actual)

461

Study Type

Interventional

Phase

Phase 3